Jonathan Cook elected as Society for Clinical Trials board member
3 April 2023
Associate Professor Jonathan Cook has been elected to the Society for Clinical Trials (SCT) board.
New approach to nail bed injury surgery could significantly cut NHS costs
30 March 2023
According to a new Oxford study, changing clinical practice for finger injuries in children could save the NHS £720,000 per year.
OCTRU - delivering answers to important clinical questions
7 March 2023
The Oxford Clinical Trials Research Unit (OCTRU) has received NIHR benchmarking results and offers excellent value for money according to the report
Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease
15 November 2022
Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.
Three NIHR HTA grants awarded to Professor Tim Theologis
4 October 2022
Congratulations to Professor Tim Theologis, who has been awarded three NIHR HTA grants to extend research in orthopaedic disorders in children.
Going straight to surgery found to be better than undergoing rehabilitation first for longstanding anterior cruciate ligament injury
23 August 2022
New research, funded by the National Institute for Health and Care Research (NIHR), shows initial surgery to be more successful and cost effective than undergoing treatment with rehabilitation first to treat longstanding anterior cruciate ligament injury.
Oxford receives NIHR funding to test anti-TNF on post operative delirium
27 July 2022
Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.
Emergency departments to use the FORCE pathway for wrist fractures in children
6 July 2022
New research from the University of Oxford has shown that doctors can simplify treatment for the most common fracture in children, reducing NHS costs.
Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination
29 June 2022
The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.
Celebrating Clinical Trials Day at NDORMS
20 May 2022
To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.
Breakthrough in treatment for Dupuytren’s disease
30 April 2022
Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.
Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain
6 April 2022
A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.